• Galectin Therapeutics reported publication of NAVIGATE Phase 2b trial results for belapectin in Hepatology; results were presented as a journal publication, not flagged for a future conference readout.
• Study tested belapectin in patients with MASH cirrhosis and portal hypertension without esophageal varices at baseline.
• Belapectin showed a reduction in new varices versus placebo, with stronger evidence in patients who adhered to protocol.
• Findings also aligned with noninvasive markers consistent with reduced fibrosis or portal hypertension risk.
• Drug was generally safe and well tolerated, supporting continued development in a population with limited treatment options.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galectin Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605110800PRIMZONEFULLFEED9715128) on May 11, 2026, and is solely responsible for the information contained therein.